NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
Bolt Biotherapeutics, Inc.
The First Affiliated Hospital of Zhengzhou University
DEKA Biosciences
Sichuan University
Tianjin Medical University Cancer Institute and Hospital